Cancer genetics and therapeutics

185 - Join the ParaGANGlioma - More Support for FH in Hereditary PGL-PCC

Previous Eposter
182 - Implementing Gene Curation for Hereditary Cancer Susceptibility in Australia: Achieving Consensus on Genes with Clinical Utility

Next Eposters
190 - Characteristics and Management of Women With CHEK2 Truncating vs. Missense Mutations After Hereditary Breast and Ovarian Cancer Gene Panel Testing
191 - Prevalence of Inherited Renal Cancer and Application of the ACMG/NSGC Genetic Referral Guidelines in University of Miami from 2014-2017
194 - Elucidating a de novo PATRR-Mediated t(3;8) Balanced Translocation Associated with Clear Cell Renal Cell Carcinoma 
198 - Information is Power: Summary of Positive Results Over Three Years of a Hereditary Cancer Population Screening Initiative
200 - There’s the Genotype! Where’s the Phenotype? A Descriptive Analysis of Hereditary Cancer Gene Variants in an Elective Genome Sequencing Population
201 - Somatic Variants and Their Risks for Malignancy in Thyroid Nodules with Indeterminate Cytology
202 - The SureMASTR BRCA Screen Solution Is An Accurate Workflow For SNV, Indel and CNV Detection In Blood- And FFPE-Derived DNA
204 - A Platform Independent Method for Calculating Aberrant Cell Fraction from Microarray and NGS Data
205 - Frequency and Characteristics of Large Deletions in Patients with Muir-Torre Syndrome
206 - Next-Generation Sequencing Panel Analysis in 2600 Hereditary Cancer Patients